Terry M. Nolan
Expertise in
3
conditions

Terry M. Nolan

792 Elizabeth St, 
Melbourne, VIC, AU 
Expertise in
3
conditions
792 Elizabeth St, 
Melbourne, VIC, AU 

Overview

Terry Nolan practices practicing medicine in Melbourne, Australia.

Mr. Nolan is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Tetanus, Pertussis, Flu, and Cerebral Hypoxia.

He is actively involved in clinical research, co-authoring 99 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

792 Elizabeth St, Melbourne, VIC 3000, Australia
Other Locations
207 Bouverie Street, Melbourne, VIC 3010, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Enrollment Status: Terminated
Publish Date: February 20, 2025
Intervention Type: Biological, Drug
Study Drug: RSV Maternal vaccine
Study Phase: Phase 3
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Combination product, Biological
Study Phase: Phase 3
A Phase I, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults Aged 18 to 64 Years Previously Vaccinated With 3 Doses of Licensed SARS-CoV-2 Ancestral Strain Vaccines
A Phase I, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults Aged 18 to 64 Years Previously Vaccinated With 3 Doses of Licensed SARS-CoV-2 Ancestral Strain Vaccines
Enrollment Status: Completed
Publish Date: May 15, 2023
Intervention Type: Other, Biological
Study Phase: Phase 1
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

99 Total Publications

Development of an adjuvanted, higher-dose, cell-based influenza vaccine: combining advanced technologies to improve vaccine effectiveness.
Development of an adjuvanted, higher-dose, cell-based influenza vaccine: combining advanced technologies to improve vaccine effectiveness.
Journal: Expert review of vaccines
Published: April 29, 2026

Frequently Asked Questions about Terry M. Nolan

Is Terry M. Nolan a top-rated expert for Tetanus?

MediFind is an objective health platform that identifies experts based on real-world data. Terry M. Nolan is classified as an Distinguished expert for Tetanus, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Terry M. Nolan participate in research or clinical trials?

Yes. Terry M. Nolan has published 99 articles and abstracts on conditions like Tetanus. You can view a list of Terry M. Nolan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Nolan's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile